On September 1, 2022, Health Canada authorized the use of Moderna Spikevax Bivalent (50 mcg) COVID-19 vaccine as a booster dose in adults aged 18 years and older. This represents the first bivalent Omicron-containing mRNA COVID-19 vaccine authorized for use in Canada
When developing these recommendations, NACI reviewed the spread and severity of Omicron variants; the level and duration of protection from COVID-19 vaccination, infection, or hybrid immunity (i.e., protection due to a combination of both infection and vaccination) in affected age groups; clinical trial data on the safety, efficacy and immune response of a booster dose of bivalent Omicron (BA.1)-containing mRNA vaccination; and ethical considerations related to COVID-19 vaccination.
- Recommendation
- Americas
- Canada
- COVID-19
